Clinical trials: Lymphoma, Malignant
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine…
- Trial name
- BRIO (NCT03370185)
- Testing
- Duvelisib
- Where
- 8 sites in United States
- Sponsor
- SecuraBio
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to…
- Trial name
- TAILOR (NCT05963074)
- Testing
- Ibrutinib, Venetoclax
- Where
- 74 sites in United States, Canada and 6 more
- Volunteers
- 333 people
- Sponsor
- Janssen Research & Development, LLC
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML)
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
The purpose of the study was to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma…
- Conditions
- Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Trial name
- NCT04702425
- Testing
- VOB560, MIK665
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Diffuse Large B-Cell Lymphoma (DLBCL).
- Trial name
- NCT02674750
- Testing
- CUDC-907
- Where
- 25 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Curis, Inc.
Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
- Trial name
- NCT00866047
- Testing
- brentuximab vedotin
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 58 people
- Sponsor
- Seagen Inc.
Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome
RPM Signals in Outpatient CAR T Therapy
The goal of this observational study is to learn how patients' vital signs and symptoms change during outpatient CAR T-cell therapy with lisocabtagene maraleucel (liso-cel), a type of cancer treatment.
- Conditions
- Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, B-Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT07882732
- Volunteers
- 125 people
- Sponsor
- Current Health
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have…
- Trial name
- NCT07139873
- Testing
- DZD8586, Bendamustine, Idelalisib
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- Dizal Pharmaceuticals
Acute Lymphoblastic Leukemia
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
This study is a single arm clinical study to observe the safety ，dose tolerance and pharmacokinetic characteristics of CAR NK-CD19 in patients with recurrent or refractory CD19 positive acute lymphoblastic leukemia, and…
- Trial name
- NCT05563545
- Testing
- CAR-NK-CD19 Cells
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Advanced Solid Tumor, Lymphoma
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or…
- Conditions
- Advanced Solid Tumor, Lymphoma, NSCLC, HCC
- Trial name
- NCT05341557
- Testing
- BPI-371153
- Where
- 4 sites in China
- Volunteers
- 110 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Hematological Malignancy, Leukemia
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
The purpose of this study is to determine the safety and anti-tumor effects of an experimental immunotherapy drug, called AlloStim, which is intentionally mis-matched immune cells which are designed to elicit the same anti-tumor…
- Conditions
- Hematological Malignancy, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00558675
- Testing
- AlloStim
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Mirror Biologics, Inc.
Prostate Cancer, Non-Hodgkins Lymphoma
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Patients with hormone and docetaxel refractory prostate cancer or relapsed/refractory non-Hodgkin's lymphoma for which no available standard therapy or therapy which may provide clinical benefit is available will be enrolled.
- Trial name
- NCT00848601
- Testing
- SGI-1776
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)
- Trial name
- NCT04930536
- Testing
- Acalabrutinib capsule
- Where
- 15 sites in India
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Lymphoma
Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma
Primary Objective: To determine if non-Hodgkin Lymphoma (NHL) participants mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal…
- Trial name
- NCT02221492
- Testing
- plerixafor GZ316455, Filgrastim
- Where
- 12 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- AUGMENT-101 (NCT04065399)
- Testing
- revumenib, cobicistat
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 447 people
- Sponsor
- Syndax Pharmaceuticals
Lymphoma, Non-Hodgkin
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
- Trial name
- NCT00045864
- Testing
- Recombinant Human Interleukin-2 and Rituximab
- Where
- 33 sites in United States
- Sponsor
- Chiron Corporation
Relapsed or Refractory Mantle Cell Lymphoma
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about…
- Trial name
- NCT01833039
- Testing
- Ibrutinib
- Where
- 51 sites in United States, Brazil and 1 more
- Sponsor
- Janssen Biotech, Inc.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell
Safety Study of SEA-CD40 in Cancer Patients
This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma
- Trial name
- NCT02376699
- Testing
- Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40
- Where
- 19 sites in United States
- Volunteers
- 159 people
- Sponsor
- Seagen Inc.
NHL, NHL, Relapsed, Adult
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
- Trial name
- NCT05879744
- Testing
- CLN-978
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Cullinan Therapeutics Inc.
Non-hodgkin's Lymphoma
Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma
Primary Outcome Measures: Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ] Secondary Outcome Measures: The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days…
- Trial name
- NCT03456466
- Testing
- TQB2303, Rituximab
- Where
- 2 sites in China
- Volunteers
- 122 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.